607 related articles for article (PubMed ID: 17029602)
41. Analysis of the role of the PAC1 receptor in neutrophil recruitment, acute-phase response, and nitric oxide production in septic shock.
Martínez C; Juarranz Y; Abad C; Arranz A; Miguel BG; Rosignoli F; Leceta J; Gomariz RP
J Leukoc Biol; 2005 May; 77(5):729-38. PubMed ID: 15661828
[TBL] [Abstract][Full Text] [Related]
42. Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves.
Fahrenkrug J; Hannibal J; Tams J; Georg B
J Cereb Blood Flow Metab; 2000 Aug; 20(8):1205-14. PubMed ID: 10950381
[TBL] [Abstract][Full Text] [Related]
43. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
[TBL] [Abstract][Full Text] [Related]
44. Characterization, expression, and functional activity of pituitary adenylate cyclase-activating polypeptide and its receptors in human granulosa-luteal cells.
Morelli MB; Barberi M; Gambardella A; Borini A; Cecconi S; Coticchio G; Canipari R
J Clin Endocrinol Metab; 2008 Dec; 93(12):4924-32. PubMed ID: 18782879
[TBL] [Abstract][Full Text] [Related]
45. Involvement of VIP and PACAP in neonatal brain lesions generated by a combined excitotoxic/inflammatory challenge.
Favrais G; Couvineau A; Laburthe M; Gressens P; Lelievre V
Peptides; 2007 Sep; 28(9):1727-37. PubMed ID: 17683829
[TBL] [Abstract][Full Text] [Related]
46. Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke.
Onoue S; Endo K; Ohmori Y; Yamada S; Kimura R; Yajima T; Kashimoto K
Regul Pept; 2004 Dec; 123(1-3):193-9. PubMed ID: 15518912
[TBL] [Abstract][Full Text] [Related]
47. Inhibitory effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) on food intake in the goldfish, Carassius auratus.
Matsuda K; Maruyama K; Nakamachi T; Miura T; Uchiyama M; Shioda S
Peptides; 2005 Sep; 26(9):1611-6. PubMed ID: 16112400
[TBL] [Abstract][Full Text] [Related]
48. Aging-Induced Modulation of Pituitary Adenylate Cyclase-Activating Peptide- and Vasoactive Intestinal Peptide-Induced Vasomotor Responses in the Arteries of Mice.
Ivic I; Solymar M; Fulop BD; Hashimoto H; Toth G; Tamas A; Juhasz T; Koller A; Reglodi D
J Vasc Res; 2017; 54(6):359-366. PubMed ID: 29131060
[TBL] [Abstract][Full Text] [Related]
49. Paradoxical antagonism of PACAP receptor signaling by VIP in Xenopus oocytes via the type-C natriuretic peptide receptor.
Lelièvre V; Hu Z; Ioffe Y; Byun JY; Flores A; Seksenyan A; Waschek JA
Cell Signal; 2006 Nov; 18(11):2013-21. PubMed ID: 16723209
[TBL] [Abstract][Full Text] [Related]
50. VIP and PACAP receptor pharmacology: a comparison of intracellular signaling pathways.
Dickson L; Aramori I; Sharkey J; Finlayson K
Ann N Y Acad Sci; 2006 Jul; 1070():239-42. PubMed ID: 16888173
[TBL] [Abstract][Full Text] [Related]
51. PACAP and VIP prevent apoptosis in schwannoma cells.
Castorina A; Tiralongo A; Giunta S; Carnazza ML; Rasi G; D'Agata V
Brain Res; 2008 Nov; 1241():29-35. PubMed ID: 18835258
[TBL] [Abstract][Full Text] [Related]
52. Vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide: effects on insulin release in isolated mouse islets in relation to metabolic status and age.
Persson-Sjögren S; Forsgren S; Lindström P
Neuropeptides; 2006 Aug; 40(4):283-90. PubMed ID: 16797701
[TBL] [Abstract][Full Text] [Related]
53. Pituitary adenylate cyclase-activating polypeptide (PACAP) can act as determinant of the tyrosine hydroxylase phenotype of dopaminergic cells during retina development.
Borba JC; Henze IP; Silveira MS; Kubrusly RC; Gardino PF; de Mello MC; Hokoç JN; de Mello FG
Brain Res Dev Brain Res; 2005 May; 156(2):193-201. PubMed ID: 16099306
[TBL] [Abstract][Full Text] [Related]
54. Development-related splicing regulates pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in the retina.
Lakk M; Szabó B; Völgyi B; Gábriel R; Dénes V
Invest Ophthalmol Vis Sci; 2012 Nov; 53(12):7825-32. PubMed ID: 23099490
[TBL] [Abstract][Full Text] [Related]
55. Role of VIP and PACAP in islet function.
Winzell MS; Ahrén B
Peptides; 2007 Sep; 28(9):1805-13. PubMed ID: 17559974
[TBL] [Abstract][Full Text] [Related]
56. Pituitary adenylate cyclase-activating polypeptide directly modulates the activity of proopiomelanocortin neurons in the rat arcuate nucleus.
Mounien L; Bizet P; Boutelet I; Gourcerol G; Fournier A; Vaudry H; Jégou S
Neuroscience; 2006 Nov; 143(1):155-63. PubMed ID: 16962718
[TBL] [Abstract][Full Text] [Related]
57. Effects of pituitary adenylate cyclase-activating polypeptide on facial nerve recovery in the Guinea pig.
Kimura H; Kawatani M; Ito E; Ishikawa K
Laryngoscope; 2003 Jun; 113(6):1000-6. PubMed ID: 12782812
[TBL] [Abstract][Full Text] [Related]
58. Role of PACAP and VIP in astroglial functions.
Masmoudi-Kouki O; Gandolfo P; Castel H; Leprince J; Fournier A; Dejda A; Vaudry H; Tonon MC
Peptides; 2007 Sep; 28(9):1753-60. PubMed ID: 17655978
[TBL] [Abstract][Full Text] [Related]
59. Lack of the PAC1 receptor alters the circadian expression of VIP mRNA in the suprachiasmatic nucleus of mice.
Georg B; Hannibal J; Fahrenkrug J
Brain Res; 2007 Mar; 1135(1):52-7. PubMed ID: 17196185
[TBL] [Abstract][Full Text] [Related]
60. Central administration of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide differentially regulates energy metabolism in chicks.
Tachibana T; Oikawa D; Adachi N; Boswell T; Furuse M
Comp Biochem Physiol A Mol Integr Physiol; 2007 May; 147(1):156-64. PubMed ID: 17291802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
